December 30, 2016 5:47pm

 

Friday marks not only the final trading day of the year, but also of the week, the month, and the quarter.

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened positive, flipped negative at the mid-day and closed negative.

Pre-open indication’s tally:  1 hits (VSTM) and 4 miss (BLCM, CYTX, JUNO and KITE)

 

Will investors be ready for the New Year … I am!

Can you afford to miss the insider view - Subscribe to translate news and interpret sentiment in the stem, cell and gene and regenerative therapy (SCGT&RT) universe layered with a current pricing metric

 

Click here for access and subscribe:  http://www.regmedinvestors.com/create-account      

 

I answer one question; in which company should investors put, keep and commit their money!

 

 

I answer one question; in which company should investors put, keep and commit their money!

 

 

U.S. stocks finished 2016 with a thud on Friday after all three major indexes ended the year with three straight days of losses for the first time since Nov. 4.

The NASDAQ closed DOWN -48.97 or -0.90% to 5,383.12 and the DOW closed DOWN -57.18 or -0.29% to 19,762.60.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 20/17 and 6 flats;                      
  • The mid-day flipped negative with an A/DL of 9/32 and 2 flats;
  • The closing bell continued negative with A/DL of 10/29 and 4 flats;

 

 

Henry’omics:

From this morning’s investor’s letter, “It’s the last trading day of 2016, and the wild year is going out with many sector investors feeling burned …! December trades caused many an equity to snap, crackle and pop!”

  • Reiterating, “See you on the new page of the calendar; if you must, “Play” the low volume pullbacks …

The sector’s deteriorating indicators combine to hurt share pricing as the overbought become oversold and then back again as volume continues at low ebb.

  • I also stated, “What might I expect – from my optimist – a bit more of fizzle, with the stem, cell, gene and regenerative sector currently  looking from my … pessimist like it won’t deliver until we have totally eradicated the traces of 2016 I.e. – once Q4 reporting is concluded.” 

“Don’t break-out the champagne, quite yet …”

  • The iShares Russell 2000 (IWM) indicated a positive pre- open +0.16% and closed DOWN -0.38%; the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed DOWN -0.65%.
  • The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded lower near 14.04, up +5.01%.

 

Stem, cell, gene and regenerative therapy (SCG&RT) stocks fell in the final trading day of the year on Friday as investors took profits from most companies as the sector’s future raises doubts, although major indexes posted strong annual gains and the Dow closed out the year.

  • The day’s losses were broad; with 29 decliners overwhelming the 10 advancers with 4 flats as trading volume was light, as is typical for the final trading week of the year.

 

Markets will be closed for the New Year’s Day holiday on Monday.

 

 

Today’s 3 biggest $ gainers included:

  • Cellectis SA (CLLS) +$0.28;
  • Regenxbio (RGNX) +$0.20;
  • Cytori (CYTX) +$0.12;

 

Today’s 3 biggest $ losers of the session were:

  • Spark Therapeutics (ONCE) -$0.68;
  • Intrexon (XON) -$0.62;
  • Applied Genetic Technologies (AGTC) -$0.50

 

 

The downside trend reflects a pricing trend range of:

  • Friday’s decliners ranged from -0.34% <MDXG> to -39.26% <NWBO> in 29 equities;
  • Thursday’s decliners ranged from -0.08% <ONCE> to -38.79% <NWBO> in 23 equities;
  • Wednesday’s decliners ranged from -0.44% <MDXG> to -39.14% <NWBO> in 35 equities;
  • Tuesday’s decliners ranged from -0.29% <RENE.L> to -38.96% <NWBO>in 24 equities;
  • Monday was a holiday;
  • Last Friday’s decliners ranged from -0.58% <AXGN>to -13.91 <ISCO>in 7 equities;

 

The upside shows a pricing trend range of:

  • Friday’s gainers ranged from +0.11% <VTGN>  to +8,63% <CYTX>  in 10 equities;
  • Thursday’s gainers ranged from +0.06% <CLLS> to +36% <KOOL> in 17 equities;
  • Wednesday’s gainers ranged from +0.89% <STML> to +4.48% <BSTG> in 6 equities;
  • Tuesday gainers ranged from +0.31% <BLUE> to +11.21% <ISCO> in 18 equities;
  • Monday was a holiday;
  • Last Friday gainers ranged from +0.58% <NWBO>to +9.45% <ADRO> in 34 equities;

 

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …

  • Friday’s 10 gainers followed Thursday’s 17after Wednesday’s 8 compared to Tuesday’s 18 following Monday’s holiday as compared to last Friday’s 34
  • Friday’s 29 decliners followed Thursday’s 23 after Wednesday’s 35 compared to Tuesday’s 24 following Monday’s holiday as compared to last Friday’s 7

 

 

Pre-open indication’s tally:  1 hit (VSTM) and 4 miss (BLCM, CYTX, JUNO and KITE)

  • Bellicum Pharmaceutical (BLCM) closed DOWN -$0.31 – miss;
  • Cytori (CYTX) closed UP +$0.12 – miss, their new ATM is buying their downside;
  • Juno Pharmaceuticals (JUNO) closed DOWN -$0.12 – miss;
  • Kite Pharma (KITE) closed DOWN -$0.41 – miss;
  • Verastem (VSTM) closed UP +$0.04 – hit;

                                                                                                          

Percentage (%) decliners:

  • Northwest Bio (NWBO) -39.26% after Thursday’s -38.79% after Wednesday’s -39.14% after Tuesday’s-38.96%;
  • Capricor (CAPR) -9.22% after Thursday’s +12.26% after Wednesday’s +1.16%;
  • Cesca Therapeutics (KOOL) +3% after Tuesday’s +6.35%;
  • Opexa (OPXA) -6.12%;
  • International Stem cell (ISCO) -5.50%

 

Percentage (%) advancers:

  • Cytori (CYTX) +8.63% after Thursday’s -7.48%;
  • ImmunoCellular (NYSEMKT: IMUC) +5.40%;
  • Verastem (VSTM) +5.40%;
  • Caladrius Biosciences (CLBS) +2.17%;
  • Athersys (ATHX) +2%

 

Flat:                                                                                                      

  • Asterias Biotherapeutics (NYSEMKT: AST) at $4.60;
  • Brainstorm Cell Therapy  (BCLI) at $2.54;
  • Sangamo (SGMO) at $3.05;

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Friday traded near 14.04;

·         Thursday traded near 13.37;

·         Wednesday traded near 12.9;

·         Tuesday traded near 12;

·         Monday was a holiday;

·         Last Friday traded near 11.6;

                                                                                                                                                                                               

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.